What Are The Types Of Lymphomas


Definition and overview of lymphoma

Lymphoma is a type of cancer that originates from lymphocytes, a type of white blood cell involved in fighting infections. This cancer has the potential to affect various tissues such as lymph nodes, bone marrow, and extranodal sites.1 

Lymphoma, although relatively less common compared to other malignancies, still holds significant importance in the realm of cancer. It accounts for approximately 5% of all diagnosed malignancies1. Despite its lower prevalence, lymphoma's impact should not be underestimated, as it presents unique challenges in terms of diagnosis, classification, and treatment strategies. Understanding and addressing the complexities of lymphoma are essential for providing optimal care to affected individuals.

In this article, we want to provide an overview of lymphomas and briefly present some of the most common types of lymphoma.

Lymphoma development is influenced by various factors, including environmental, infectious, genetic, and immunological factors. Occupational exposure to certain substances, such as herbicides and pesticides, has been linked to an increased risk of lymphoma. Infections caused by organisms like Helicobacter pylori, Borrelia burgdorferi, and hepatitis C virus have been associated with specific lymphoma subtypes. Epstein Barr virus and cytomegalovirus,2,3 as well as immunodeficiency conditions, such as HIV infection and genetic immunodeficiency disorders,4 also increase the risk of lymphoma. Certain medications, autoimmune diseases, and chronic stimulation of lymphoid tissue due to persistent infections further contribute to the development of lymphoma. 

Importance of understanding lymphoma types

Understanding the different types of lymphoma is really important for several reasons. Firstly, accurate classification and subtyping of lymphoma enable healthcare professionals to make precise diagnoses, which in turn guide appropriate treatment strategies. Each lymphoma subtype possesses unique clinical, pathological, and genetic characteristics that influence prognosis and treatment response.5 Furthermore, advancements in molecular research have revealed distinct subtypes within lymphoma, leading to the identification of specific genetic alterations, signalling pathways, and biomarkers that can serve as targets for novel therapies.6 Lastly, understanding lymphoma types aids in conducting meaningful research, facilitating clinical trials, and sharing knowledge among healthcare professionals, ultimately contributing to advancements in the field.7 

Hodgkin lymphoma

Definition and characteristics of hodgkin lymphoma

Hodgkin lymphoma is a type of cancer characterized by the presence of abnormal cells called Hodgkin Reed-Sternberg (HRS) cells. These cells usually originate from B-cells and are found in the context of different tissue backgrounds. Classical Hodgkin lymphoma is divided into four main types: nodular sclerosing, mixed cellularity, lymphocyte-rich, and lymphocyte-depleted. There is also a non-classical type called nodular lymphocyte-predominant Hodgkin lymphoma.

This lymphoma can occur at two different age peaks, one in the early 20s and another in the mid-60s.

Clinical features, diagnosis, and staging of hodgkin lymphoma

The distinguishing feature of the classic forms of Hodgkin lymphoma is the presence of cells called Reed-Sternberg, which are large multinucleated cells with two mirror-image nuclei that resemble owl eyes. Nodular lymphocyte-predominant Hodgkin lymphoma does not exhibit the typical Reed-Sternberg but is characterized by the presence of lymphocytic and histiocytic cells. These cells are larger and have folded multilobulated nuclei, often referred to as "popcorn cells", and display nuclei with multiple basophilic nucleoli that are smaller compared to those observed in Reed-Sternberg cells.

To confirm a diagnosis of Hodgkin lymphoma, a biopsy of a lymph node or suspected organ is necessary. Laboratory tests, including a complete blood count; and imaging scans such as chest x-ray, CT, and PET/CT scans play a crucial role in determining the stage of the disease, which is important because the type of treatment is dependent on its stage.

The staging system commonly used for Hodgkin lymphoma classifies the disease into four stages:

  • Stage I: the lymphoma affects a single lymph node region or lymphoid structure
  • Stage II: the lymphoma involves two or more lymph node regions on the same side of the diaphragm
  • Stage III: the lymphoma affects lymph nodes or structures on both sides of the diaphragm
  • Stage IV: the lymphoma extends to extranodal sites

Treatment options for hodgkin lymphoma

The treatment approach for Hodgkin lymphoma depends on various factors, including histologic characteristics, disease stage, and prognostic factors. The primary goal of treatment is to achieve a cure while minimizing both short-term and long-term complications. For patients with early-stage disease and favourable prognostic features, a shorter duration of chemotherapy followed by restricted radiation therapy to the affected area is typically administered. In cases of limited-stage disease with unfavourable features, a longer course of chemotherapy (4 to 6 cycles) is followed by a higher dose of involved-field radiation therapy. For patients with advanced-stage disease different chemotherapy regimens are chosen according to the severity of the disease.8

Non hodgkin lymphoma (NHL)

Definition and characteristics of non hodgkin lymphoma

Non-Hodgkin lymphoma is a type of cancer that originates from different types of lymphoid tissues, including B cells and T cells at various stages of maturation. It can be categorized into two groups based on prognosis: indolent (slow-growing) and aggressive (fast-growing). Common types of Non-Hodgkin lymphoma include follicular lymphoma, Burkitt lymphoma, diffuse large B cell lymphoma, mantle cell lymphoma, marginal zone lymphoma, primary CNS lymphoma, adult T cell lymphoma, and mycosis fungoides.9 Indolent lymphomas often present with fluctuating lymph node enlargement over many years, while aggressive lymphomas cause specific symptoms like weight loss, night sweats, and fever, and can lead to rapid deterioration if not treated. Peripheral lymphadenopathy is a common symptom, although other manifestations such as skin rashes, increased sensitivity to insect bites, fatigue, itching, unexplained fever, ascites, and fluid accumulation can also occur. Non-Hodgkin lymphoma is more prevalent in individuals aged 65 to 74, with a median age of diagnosis around 67 years.10

Clinical features, diagnosis, and staging of NHL

The diagnosis of Non-Hodgkin Lymphoma includes several steps. A complete blood count is performed to assess for abnormalities such as anaemia, low platelet count, and abnormal white blood cell counts. Serum chemistry tests help evaluate for tumour lysis syndrome and liver involvement. Imaging, such as CT scans or PET scans, is conducted to determine the extent of the disease. Lymph node and tissue biopsy are crucial for diagnosis, with excisional biopsy being the preferred method.11 Lumbar puncture may be performed in high-risk cases to assess for central nervous system involvement. Immunophenotypic analysis of lymph nodes, peripheral blood, and bone marrow aids in characterizing the lymphoma subtype. Bone marrow aspiration and biopsy may be necessary for staging purposes, although their use is declining due to the availability of PET scans.

The current staging system used for Non-Hodgkin Lymphoma is the Lugano classification. As well as for Hodgkin's lymphoma, four stages are recognized:

  • Stage I: indicates involvement of a single lymph node region or a single extranodal site without nodal involvement
  • Stage II: refers to the involvement of two or more lymph node regions on one side of the diaphragm or localized involvement of an extranodal site
  • Stage III: indicates lymph node involvement on both sides of the diaphragm
  • Stage IV: indicates widespread involvement of one or more extranodal organs, with or without associated lymph node involvement

Treatment options for NHL

The treatment of Non-Hodgkin lymphoma depends on factors such as the specific type, stage, histopathological features, and symptoms. Common treatment options include chemotherapy, radiotherapy, immunotherapy, stem cell transplant, and occasionally surgery. A commonly used approach is chemoimmunotherapy, which combines chemotherapy with immunotherapy drugs like rituximab. Radiation therapy is primarily used for early-stage lymphoma (Stage I, II). For more advanced stages a combination of chemotherapy, immunotherapy, targeted therapy, and sometimes radiation therapy is employed.12

Primary central nervous system lymphoma (PCNSL)

Definition and characteristics of PCNSL

Primary central nervous system lymphoma (PCNSL) is an aggressive type of non-Hodgkin lymphoma that specifically affects the central nervous system (CNS), including the brain, spine, cerebrospinal fluid (CSF), and eyes. Unlike many other brain tumours, PCNSL generally responds well to chemotherapy and radiation therapy. However, when PCNSL does not respond to initial treatment, the overall prognosis is typically worse.13 

Clinical features, diagnosis, and staging of PCNSL

Patients with PCNSL experience neurological symptoms over a period of weeks. These symptoms can include focal neurological deficits (such as weakness or numbness in specific body parts), changes in mental status and behaviour, symptoms related to increased pressure in the brain (such as headaches, nausea, vomiting, swelling of the optic nerve), and seizures.14 The specific symptoms depend on which parts of the central nervous system are affected.

To diagnose the disease, doctors recommend performing several tests. These include an MRI of the brain (and spine if spinal symptoms are present), evaluation by an eye specialist, and examination of the CSF. Additional tests such as a PET/CTS of the body and a bone marrow biopsy may be done to check for the involvement of non-central nervous system areas. To confirm the diagnosis of PCNSL, a stereotactic biopsy (a procedure that uses imaging guidance to obtain a tissue sample) is usually performed. In some cases, if there is evidence of eye or CSF involvement, a vitrectomy (removal of fluid from the eye) or CSF cytology (examination of CSF cells) may be sufficient for diagnosis.15

Treatment options for PCNSL

The treatment approach for PCNSL has undergone changes in recent years, but there is currently no universally agreed-upon consensus regarding the best treatment regimen. However, experts in the field concur that high-dose methotrexate (HD-MTX) plays a central role in multimodal therapy, which may involve the use of other chemotherapy drugs along with or without radiation. Several aspects of treatment remain controversial, including the role of surgery, the most effective initial chemotherapy regimen, the necessity of radiation therapy, and how to address the treatment of the cerebrospinal fluid space.

Cutaneous lymphoma

Definition and characteristics of cutaneous lymphoma

Cutaneous lymphomas are a diverse group of lymphoid neoplasms that primarily affect the skin. They can be classified into two main categories: primary cutaneous lymphomas, which originate in the skin, and secondary cutaneous lymphomas, which involve the skin as part of a systemic lymphoma.16 It is important to note that cutaneous lymphoma has different prognoses and treatment approaches compared to systemic lymphomas that share similar histological features.

Clinical features, diagnosis, and staging of cutaneous lymphoma

The clinical presentation of cutaneous lymphomas can vary widely and depends on the specific subtype. Common clinical features include skin lesions, such as erythematous patches, plaques, nodules, or tumours on the skin, that may be localized or widespread, pruritus, skin ulceration, and in aggressive forms, systemic symptoms such as fever, weight loss, and night sweats.17

The diagnosis of cutaneous lymphoma involves a combination of clinical, histopathological, immunophenotypic, and molecular studies. Key steps in the diagnostic process include skin biopsy, essential for establishing the diagnosis, on which histopathological examination is performed; immunohistochemistry or flow cytometry, used to determine the immunophenotype of the lymphoma cells; and molecular studies to detect specific genetic abnormalities associated with certain subtypes of cutaneous lymphoma.18

Treatment options for cutaneous lymphoma

Treatment options for cutaneous lymphoma are determined by factors like the subtype, stage, and individual patient characteristics. Common treatments include topical therapies, phototherapy, radiation therapy, and systemic therapies such as chemotherapy, immunotherapy, targeted therapies, and stem cell transplant.19 Decisions regarding treatment should involve a multidisciplinary team and consider the specific subtype and stage of the lymphoma, as well as the patient's overall health and preferences. Consulting healthcare professionals is essential for accurate diagnosis and treatment recommendations.


While we have attempted to provide a concise overview of lymphomas, it is important to acknowledge the complexity and diversity of this topic. Due to the numerous subtypes of lymphoma, their distinct characteristics, diagnostic methods, and treatment options, it is impossible to delve into each one in detail within this summary. It is crucial to consult with a medical specialist for accurate information and personalized advice. Our intention was to highlight the wide range of lymphoma subtypes and emphasize the significance of understanding their differences to determine the most suitable treatment approach.


  1. Lewis, William D., et al. «Lymphoma: Diagnosis and Treatment». American Family Physician, vol. 101, fasc. 1, gennaio 2020, pp. 34–41.
  2. Said, W., et al. «Kaposi’s Sarcoma-Associated Herpesvirus (KSHV or HHV8) in Primary Effusion Lymphoma: Ultrastructural Demonstration of Herpesvirus in Lymphoma Cells». Blood, vol. 87, fasc. 12, giugno 1996, pp. 4937–43.
  3. Hjalgrim, Henrik, et al. «Characteristics of Hodgkin’s Lymphoma after Infectious Mononucleosis». New England Journal of Medicine, vol. 349, fasc. 14, ottobre 2003, pp. 1324–32. DOI.org (Crossref), https://doi.org/10.1056/NEJMoa023141.
  4. Biggar, Robert J., et al. «Hodgkin Lymphoma and Immunodeficiency in Persons with HIV/AIDS». Blood, vol. 108, fasc. 12, dicembre 2006, pp. 3786–91. DOI.org (Crossref), https://doi.org/10.1182/blood-2006-05-024109.
  5. Swerdlow, Steven H., et al. «The 2016 Revision of the World Health Organization Classification of Lymphoid Neoplasms». Blood, vol. 127, fasc. 20, maggio 2016, pp. 2375–90. DOI.org (Crossref), https://doi.org/10.1182/blood-2016-01-643569.
  6. Schmitz, Roland, et al. «Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma». New England Journal of Medicine, vol. 378, fasc. 15, aprile 2018, pp. 1396–407. DOI.org (Crossref), https://doi.org/10.1056/NEJMoa1801445.
  7. Cheson, Bruce D., et al. «Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification». Journal of Clinical Oncology, vol. 32, fasc. 27, settembre 2014, pp. 3059–67. DOI.org (Crossref), https://doi.org/10.1200/JCO.2013.54.8800.
  8. Kaseb, Hatem, e Hani M. Babiker. «Hodgkin Lymphoma». StatPearls, StatPearls Publishing, 2023. PubMed, http://www.ncbi.nlm.nih.gov/books/NBK499969/.
  9. Armitage, J. O., e D. D. Weisenburger. «New Approach to Classifying Non-Hodgkin’s Lymphomas: Clinical Features of the Major Histologic Subtypes. Non-Hodgkin’s Lymphoma Classification Project.» Journal of Clinical Oncology, vol. 16, fasc. 8, agosto 1998, pp. 2780–95. DOI.org (Crossref), https://doi.org/10.1200/JCO.1998.16.8.2780.
  10. Smith, A., et al. «Incidence of Haematological Malignancy by Sub-Type: A Report from the Haematological Malignancy Research Network». British Journal of Cancer, vol. 105, fasc. 11, novembre 2011, pp. 1684–92. DOI.org (Crossref), https://doi.org/10.1038/bjc.2011.450.
  11. Steinfort, Daniel P., et al. «Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration for the Evaluation of Suspected Lymphoma». Journal of Thoracic Oncology, vol. 5, fasc. 6, giugno 2010, pp. 804–09. DOI.org (Crossref), https://doi.org/10.1097/JTO.0b013e3181d873be.
  12. Sapkota, Sumina, e Hira Shaikh. «Non-Hodgkin Lymphoma». StatPearls, StatPearls Publishing, 2023. PubMed, http://www.ncbi.nlm.nih.gov/books/NBK559328/.
  13. Grommes, Christian, e Lisa M. DeAngelis. «Primary CNS Lymphoma». Journal of Clinical Oncology, vol. 35, fasc. 21, luglio 2017, pp. 2410–18. DOI.org (Crossref), https://doi.org/10.1200/JCO.2017.72.7602.
  14. Bataille, Benoit, et al. «Primary intracerebral malignant lymphoma: report of 248 cases». Journal of Neurosurgery, vol. 92, fasc. 2, febbraio 2000, pp. 261–66. DOI.org (Crossref), https://doi.org/10.3171/jns.2000.92.2.0261.
  15. Abrey, Lauren E., et al. «Report of an International Workshop to Standardize Baseline Evaluation and Response Criteria for Primary CNS Lymphoma». Journal of Clinical Oncology, vol. 23, fasc. 22, agosto 2005, pp. 5034–43. DOI.org (Crossref), https://doi.org/10.1200/JCO.2005.13.524.
  16. Willemze, Rein, et al. «The 2018 Update of the WHO-EORTC Classification for Primary Cutaneous Lymphomas». Blood, vol. 133, fasc. 16, aprile 2019, pp. 1703–14. DOI.org (Crossref), https://doi.org/10.1182/blood-2018-11-881268.
  17. Kempf, Werner, et al. «Cutaneous Lymphomas—An Update 2019». Hematological Oncology, vol. 37, fasc. S1, giugno 2019, pp. 43–47. DOI.org (Crossref), https://doi.org/10.1002/hon.2584.
  18. Specht, L., e L. Skov. «Cutaneous Lymphomas». Clinical Oncology, vol. 31, fasc. 11, novembre 2019, pp. 797–807. DOI.org (Crossref), https://doi.org/10.1016/j.clon.2019.07.018.
  19. Wobser, Marion, e Matthias Goebeler. «Kutane Lymphome: Klinik – Diagnostik – Therapie». Der Pathologe, vol. 41, fasc. 1, febbraio 2020, pp. 79–94. DOI.org (Crossref), https://doi.org/10.1007/s00292-019-00743-1.
This content is purely informational and isn’t medical guidance. It shouldn’t replace professional medical counsel. Always consult your physician regarding treatment risks and benefits. See our editorial standards for more details.

Get our health newsletter

Get daily health and wellness advice from our medical team.
Your privacy is important to us. Any information you provide to this website may be placed by us on our servers. If you do not agree do not provide the information.

Eleonora Hay

Doctor of Philosophy - PhD, Medical, clinical and experimental sciences, University of Campania "Luigi Vanvitelli"

I am a biologist and a PhD in Medical, Clinical, and Experimental Sciences. I have a strong background in basic research and throughout my career, I have had the opportunity to work in academic settings across Italy and Germany, gaining invaluable experience in the field. I have always nurtured a passion for writing. Recognizing the potential to merge my love for science with my writing skills, I made the decision to venture into the realm of scientific and medical writing after completing my doctorate. Recently, I began freelancing with companies specializing in scientific and medical writing services. Motivated by a desire to expand my knowledge in the field of clinical research, I am currently attending a theoretical course centered on Good Clinical Practice, Clinical Research, and Clinical Trials Monitoring and Management.

my.klarity.health presents all health information in line with our terms and conditions. It is essential to understand that the medical information available on our platform is not intended to substitute the relationship between a patient and their physician or doctor, as well as any medical guidance they offer. Always consult with a healthcare professional before making any decisions based on the information found on our website.
Klarity is a citizen-centric health data management platform that enables citizens to securely access, control and share their own health data. Klarity Health Library aims to provide clear and evidence-based health and wellness related informative articles. 
Klarity / Managed Self Ltd
Alum House
5 Alum Chine Road
Westbourne Bournemouth BH4 8DT
VAT Number: 362 5758 74
Company Number: 10696687

Phone Number:

 +44 20 3239 9818